Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Kratom‑regulation topic
No spam. Unsubscribe anytime.
Committee advances kratom bill with age restrictions and packaging rules; debate centers on 7‑OH concentration cap
Summary
AB 1088 would set a minimum sales age of 21 for kratom products, require child‑resistant packaging and ban marketing that targets minors; it would also limit concentrated 7‑hydroxy‑mitragynine (7‑OH) but drew opposition over the proposed 2% cap and enforcement concerns.
AB 1088, presented by Assemblymember Baines, would regulate kratom products sold in California by imposing a minimum purchaser age of 21, requiring child‑resistant packaging, banning marketing that appeals to children, and limiting the concentration of the semi‑synthetic alkaloid 7‑hydroxy‑mitragynine (7‑OH) in kratom products.
Proponents — including public‑health witnesses, the California Narcotic Officers Association, and several county sheriff and police organizations — told the committee kratom is widely available at convenience stores and online and raised concerns about concentrated 7‑OH products, respiratory depression, seizures and addiction risks. Dr. Baines and other proponents said concentrated 7‑OH presents risks similar to opioid exposure and that sufficient packaging and age limits are appropriate public‑health measures.
Opponents — including representatives of kratom advocacy and industry groups and some harm‑reduction advocates and former law‑enforcement members — supported age limits and child‑safety packaging but opposed the bill’s 2% cap on 7‑OH. They argued the 2% concentration limit could be a de facto ban, create enforcement loopholes (manufacturers could dilute by adding more mitragynine), and restrict access for adults who report therapeutic benefit. Several witnesses asked the author to consider a milligram‑based cap tied to scientific study rather than a percentage cap, or to continue technical work so regulation does not push consumers to illicit markets.
The committee recorded a motion to move AB 1088 to the Appropriations Committee and asked parties to continue technical conversations about measurement and enforcement. The chair indicated an aye recommendation; members noted the need for better scientific data on 7‑OH concentrations and the difficulty of policing novel concentrated extracts sold in small doses.
Ending: Sponsors and opposition signaled willingness to continue technical work; the committee moved the bill to appropriations so fiscal and regulatory details can be examined further.
